ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO712

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Patients With IgA Nephropathy

Session Information

Category: Glomerular Diseases

  • 1303 Glomerular Diseases: Clinical‚ Outcomes‚ and Trials


  • Rizk, Dana, University of Alabama at Birmingham, Birmingham, Alabama, United States
  • Perkovic, Vlado, University of New South Wales, Sydney, New South Wales, Australia
  • Lafayette, Richard A., Stanford University, Stanford, California, United States
  • Trimarchi, Hernan, Hospital Britanico de Buenos Aires, Buenos Aires, Argentina
  • Barratt, Jonathan, University of Leicester, Leicester, Leicestershire, United Kingdom
  • Carroll, Kevin, KJC Statistics, London, United Kingdom
  • Tesar, Vladimir, Charles University, Prague, Czechia
  • Zhang, Hong, Peking University, Beijing, Beijing, China
  • Suzuki, Yusuke, Juntendo Daigaku, Bunkyo-ku, Tokyo, Japan
  • Liew, Adrian, Mount Elizabeth Novena Hospital, Singapore, Singapore
  • Wong, Muh Geot, Concord Repatriation General Hospital, Concord, New South Wales, Australia
  • Leslie, Bruce R., Otsuka Pharmaceuticals Development & Commercialization, Inc., Rockville, Maryland, United States
  • Mathur, Mohit, Visterra Inc, Boston, Massachusetts, United States
  • Hafkin, Jeffrey, Otsuka Pharmaceuticals Development & Commercialization, Inc., Rockville, Maryland, United States

IgAN is the leading primary glomerulonephritis worldwide. Up to 40% of patients develop kidney failure within ~20 years of diagnosis. Current treatment consists of optimized supportive care including renin-angiotensin aldosterone system (RAAS) blockade. New therapies targeting the underlying disease pathophysiology are needed. Emerging data suggest that the B cell growth factor, A Proliferation Inducing Ligand (APRIL), plays a key role in the pathogenesis of IgAN and may be an ideal target. Sibeprenlimab (VIS649), a humanized IgG2 monoclonal antibody (mAb) that inhibits APRIL, is being evaluated for the treatment of IgAN.


The VISIONARY Trial (NCT05248646) is a global Phase 3 randomized controlled trial which will assess the efficacy and safety of sibeprenlimab in adult patients with IgAN. Approximately 450 patients with biopsy-confirmed IgAN will be randomized to receive 400mg sibeprenlimab subcutaneously or placebo for 24 months, while continuing to receive standard of care. Key inclusion criteria: on maximally tolerated RAAS blockade, 24 hr uPCR ≥ 0.75 g/g or urine protein ≥ 1.0 g/day, eGFR ≥ 30 mL/min/1.73 m2. Patients with secondary IgAN, coexisting kidney disease, IgG < 600 mg/dL, MEST-C score T2 or C2 will not be included in the study. An exploratory cohort of 20 patients with eGFR 20-30 mL/min/1.73 m2 will also be enrolled. The primary efficacy endpoint is to evaluate the change in 24 hr uPCR at 9 months compared with baseline. Key secondary efficacy endpoint is to evaluate the change in annualized eGFR slope over 24 months. Additional secondary endpoints include clinical remission, safety, pharmacodynamics, and anti-drug Ab. Patients completing the trial will be eligible for a 24-month open label extension study (NCT05248659).


Results of study expected later when study is complete.


Sibeprenlimab is a mAb that blocks APRIL, a B cell growth factor implicated in the pathogenesis of IgAN. A pivotal phase 3 trial is under way to assess the efficacy and safety of sibeprenlimab for the treatment of IgAN.


  • Commercial Support – Otsuka Pharmaceuticals Development & Commercialization, Inc.